ImmunoGen Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Provides Quarterly Business Update
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today provided an update on the Company’s progress and reported financial results for its fourth quarter and fiscal year ended June 30, 2016.